SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-002206
Filing Date
2023-02-03
Accepted
2023-02-03 16:04:16
Documents
19
Period of Report
2023-02-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20230202.htm   iXBRL 8-K 42122
2 EX-1.1 ex-11underwritingagreement.htm EX-1.1 299454
3 EX-4.1 ex-41formofcommonstockpurc.htm EX-4.1 100062
4 EX-5.1 ex-51opinionofwyrick.htm EX-5.1 10117
5 EX-99.1 ex-991cmpolaunch.htm EX-99.1 13801
6 EX-99.2 ex-992cmpopricing.htm EX-99.2 13395
10 GRAPHIC avalologoa.jpg GRAPHIC 8535
11 GRAPHIC avalologob.jpg GRAPHIC 8535
  Complete submission text file 0001628280-23-002206.txt   729998

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20230202.xsd EX-101.SCH 1967
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20230202_lab.xml EX-101.LAB 24181
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20230202_pre.xml EX-101.PRE 12574
13 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20230202_htm.xml XML 10011
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 23585716
SIC: 2834 Pharmaceutical Preparations